StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AARD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.49 | $4.36 | -2.90% | 0.3M |
| 05-19 | $4.32 | $4.37 | +1.16% | 0.1M |
| 05-20 | $4.41 | $4.29 | -2.72% | 0.2M |
| 05-21 | $4.30 | $4.51 | +4.88% | 0.2M |
| 05-22 | $4.50 | $4.54 | +0.89% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-22.46M | $-62.73M | $-44.02M | $-26.32M |
Net Income | $-21.59M | $-57.59M | $-39.99M | $-23.68M |
EPS (Diluted) | $-0.99 | $-2.93 | $-2.12 | $-1.36 |
Total Assets | $98.59M | $117.18M | $133.23M | $147.47M |
Total Liabilities | $11.60M | $10.55M | $10.85M | $10.55M |
Cash & Equivalents | $62.44M | $47.05M | $39.28M | $26.00M |
Free Cash Flow OCF − CapEx | Not available | $-54.27M | $-37.46M | $-21.32M |
Shares Outstanding | 21.82M | 21.82M | 21.75M | 21.69M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.